Iran Among First 5 Producers of Ibrutinib In World

Speaking in an interview with Hamshahri Online, CEO of Zist Takhmir Company Sahar Bahmani said that access to foreign cancer treatment is not available due to the skyrocketing costs.

The production of ibrutinib was an almost 5-year project, she added.

Since 1397, its initiative was proposed as a fundamental project in the company, she noted.

Many people in Iran are suffering from this disease and were involved in treatments that were very expensive, she noted.

She went on to say that ibrutinib has many foreign samples and all of them are licensed and approved by the US Food and Drug Administration.

Of course, importing it is very expensive for both the country and the patient, she stressed.

Ibrutinib with the brand name Berocca is available in 140 ml and 420 ml doses in the country's pharmacies, she stated.

This drug is currently sold at 20 million tomans per package, she said.